Product Information
BUPROPION HCL SR 150 MG TABLET is a generic product labeled by ScieGen Pharmaceuticals, Inc., priced at $0.0799 per EA under NDC 50228017501. Its NADAC has been published 321 times since Aug 12, 2020.
FDA first approved this application on Mar 1, 2016. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
ScieGen Pharmaceuticals, Inc.NDC
50228017501
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BUPROPION HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA205794FDA Approved
3/1/2016
TE Code
AB1
On Market Since
4/20/2018
Pharmacological Classes
Price Statistics
The NADAC for BUPROPION HCL SR 150 MG TABLET has been published 321 times since Aug 12, 2020, and over the history we have for it it has declined 33.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0799 per EA |
|---|---|
| All-time high | $0.1199 (Aug 12, 2020) |
| All-time low | $0.0709 (May 22, 2024) |
| 52-week high | $0.0840 |
| 52-week low | $0.0799 |
| Median price | $0.0877 |
| Average price | $0.0927 |
| Largest weekly change | +20.0% (Jun 19, 2024) |
| Weeks tracked | 321 |
| Tracking since | Aug 12, 2020 |
Generic Alternatives
The matcher finds 14 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ScieGen Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
bupropion hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoketone class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPROPION HCL SR 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUPROPION HCL SR 150 MG TABLET, manufactured by ScieGen Pharmaceuticals, Inc., is $0.0799 per EA (NDC 50228017501), effective Sep 30, 2026.
How has the price of BUPROPION HCL SR 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUPROPION HCL SR 150 MG TABLET has declined 33.4%. It has been tracked across 321 weekly CMS publications since Aug 12, 2020.
What are the highest and lowest recorded NADAC prices for BUPROPION HCL SR 150 MG TABLET?
Since Aug 12, 2020, the NADAC for BUPROPION HCL SR 150 MG TABLET has ranged from a low of $0.0709 (May 22, 2024) to a high of $0.1199 (Aug 12, 2020), with a median of $0.0877 per EA.
Are there cheaper alternatives to BUPROPION HCL SR 150 MG TABLET?
Yes. 14 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BUPROPION HCL XL 150 MG TABLET, is $0.0779 per EA — about 2% below BUPROPION HCL SR 150 MG TABLET.
Who manufactures BUPROPION HCL SR 150 MG TABLET?
BUPROPION HCL SR 150 MG TABLET (NDC 50228017501) is labeled by ScieGen Pharmaceuticals, Inc., and CMS classifies it as a generic product.